– USA, CA – Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced the appointment of Dr. Monica Bertagnolli to its board of directors.
“We are delighted to welcome Dr. Bertagnolli to our board at this exciting time in Natera’s growth,” said CEO, Steve Chapman. “Her distinguished career as a leading oncology researcher and her extensive clinical experience will be instrumental in helping us execute on our vision of making bespoke MRD testing the standard of care worldwide.”
About Dr. Monica Bertagnolli
Dr. Bertagnolli is currently Professor of Surgery at Harvard Medical School and an Associate Surgeon in the Division of Surgical Oncology at Brigham and Women’s Hospital and Dana-Farber Cancer Institute. Her additional roles include Chair of the Board of Directors of the Association for Clinical Oncology and Group Chair of the Alliance for Clinical Trials in Oncology.
“Natera has emerged as an innovative and dynamic leader in ctDNA technology,” said Dr. Bertagnolli. “I’m looking forward to contributing to the company’s success as it introduces SignateraTM technology into clinical research and clinical practice. I believe this technology has the potential to change how oncologists practice medicine and significantly improve patient outcomes.”
In addition to several major committees and board advisory appointments, Dr. Bertagnolli serves as CEO of Alliance Foundation Trials, LLC, a not-for-profit organization that conducts international cancer clinical trials and is VP of the Coalition of Cancer Cooperative Groups.
She received her undergraduate degree in engineering from Princeton University and her medical degree from the University of Utah College of Medicine.
Natera is a global leader in cell-free DNA testing. The mission of the company is to change the management of disease worldwide with a focus on women’s health, oncology, and organ health. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments in San Carlos, Calif. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform.
For more information: https://www.natera.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.